Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

T-cell therapies

ASH 2009

Published: 27 Jan 2010

Views: 10725

Rating:

Save

Dr Catherine Bollard - Baylor College of Medicine, Texas, USA

Dr Catherine Bollard discusses novel T-cell therapies and the work of her laboratory.

Related Videos

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma...

Dr Jonathan Friedberg - University of Rochester, Rochester, USA

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy ( Dr Jonathan Friedberg - University of Rochester, Rochester, USA )

The evolving paradigm in management of Multiple Myeloma

D Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

The evolving paradigm in management of Multiple Myeloma ( D Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen...

CAR-T therapy and impact to cancer patient outcomes and experience of treatment ( Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen, Switzerland )

Haemato-oncological Cancers

Dr Nikita Mehra - Cancer Institute (WIA), Chennai, India

Haemato-oncological Cancers ( Dr Nikita Mehra - Cancer Institute (WIA), Chennai, India )

Haematology malignancies and cellular therapy

Dr Hugo Fernandez - Moffitt Cancer Center, Tampa, USA

Haematology malignancies and cellular therapy ( Dr Hugo Fernandez - Moffitt Cancer Center, Tampa, USA )

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

$Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )$

Triplets for newly diagnosed unfit AML patients could be feasible with...

Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain

Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )

More from ecancer